UBS Group’s Revolution Medicines RVMD Stock Holding History

UBS Group’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.31M	Sell	7,000 -500	-7%	-$73K	﹤0.01%	5495
2026 Q1	$729K	Buy	+7,500	New	+$757K	﹤0.01%	5797

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

UBS Group's RVMD Position: Q2 2026 in Review

UBS Group increased its Revolution Medicines (RVMD) stake by 24% in Q2 2026, buying an estimated $155M and bringing the position to 5,448,364 shares worth $1.02B. The position accounts for 0.13% of the portfolio, ranked #145.

UBS Group first reported a position in RVMD in Q1 2020 and has held it in 25 quarters since. 693 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

UBS Group held 5,448,364 shares of Revolution Medicines worth $1.02B as of Q2 2026.
UBS Group bought 1,061,573 Revolution Medicines shares in Q2 2026, an estimated $155M.
Revolution Medicines made up 0.13% of UBS Group's portfolio in Q2 2026, its #145 holding.
UBS Group first reported a position in Revolution Medicines in Q1 2020 and has held it in 25 quarters since.
693 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.